Forced Degradation Studies in Analytical Method Development for Pharmaceuticals: A Comprehensive Review
Abstract
Forced degradation studies, also known as stress testing, are essential tools in pharmaceutical analysis for understanding the intrinsic stability of drug substances and products. These studies involve subjecting drugs to extreme conditions to generate degradation products, thereby enabling the development of stability-indicating analytical methods. Such methods are critical for accurately distinguishing the active pharmaceutical ingredient from its degradation impurities, ensuring drug safety, efficacy, and quality. Typically, forced degradation is performed under a variety of stress conditions, including acidic and alkaline hydrolysis, oxidative degradation, thermal stress, and photolytic exposure. Each condition provides insight into specific degradation pathways and mechanisms. Advanced analytical techniques such as high-performance liquid chromatography (HPLC), liquid chromatography–mass spectrometry (LC–MS), gas chromatography–mass spectrometry (GC–MS), and photodiode array (PDA) detection are widely employed for the separation, identification, and characterisation of degradation products. These studies play a pivotal role in method development, validation, impurity profiling, and regulatory submissions. Overall, forced degradation studies are indispensable in ensuring the development of robust, reliable, and stability-indicating analytical methods in the pharmaceutical industry.
Keywords:
Forced degradation, Stress testing, Stability-indicating method, Impurity profiling, RP-HPLC, LC-MS, ICH guidelines
Downloads
Download data is not yet available.
References
1. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—A review. J Pharm Anal. 2014;4(3):159–65.
2. Singh S, Bakshi M. Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm Technol. 2000;24(2):1–14.
3. ICH. Q1A(R2): Stability Testing of New Drug Substances and Products. International Council for Harmonisation; 2003.
4. Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, et al. The role of degradant profiling in pharmaceutical development. Adv Drug Deliv Rev. 2007;59(1):29–37.
5. ICH Q1A (R2), International Council for Harmonisation, 2003.
6. ICH Q1B, ICH, 1996.
7. ICH Q2 (R1), ICH, 2005.
8. Kovarik J.M., Mueller E.A., van Bree J.B., Tetzloff W., Kutz K. (1994). Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. Journal of Pharmaceutical Sciences, 83(3), 444–446.
9. Alsante K.M., Hatajik T.D., Lohr L.L., Sharp T.R. (2003). Isolation and identification of process-related impurities and degradation products from pharmaceutical drug candidates. Part 1. American Pharmaceutical Review, 6(1), 70–78.
10. Smela J.W. (2001). Regulatory considerations for impurities in drug products. Pharmaceutical Technology, 25(6), 56–60.
11. Kavita Chandramore, Sandeep Sonawane. Overview on Development and Validation of Force Degradation Studies with Stability Indicating Methods. Biosciences Biotechnology Research Asia. 2022 Dec 20;19(4):881–94.
12. Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Juçara Ribeiro Franca, et al. Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective. Journal of Pharmaceutical Sciences. 2023 Sep 1;112(12).
13. Roberto de Alvarenga Junior B, Lajarim Carneiro R. Chemometrics Approaches in Forced Degradation Studies of Pharmaceutical Drugs. Molecules. 2019 Oct 22;24(20):3804.
14. Kronsbein K, Nold V, Böhrer A, Presser B, Gaissmaier T, Schindowski K, et al. Advancing forced degradation studies: Design of experiments for enhanced structure-function relationship analysis in biotherapeutics. European Journal of Pharmaceutics and Biopharmaceutics. 2025 Sep;214:114787.
15. Mullani AK and Nargatti PI: Forced degradation study - a new approach for stress testing of drug substances and drug products. Int J Pharm Sci & Res 2021; 12(5): 2683-91
16. Deokate U, Gorde A. Forced degradation and stability testing: Strategies and analytical perspectives. PharmaTutor. 2014 Jun 1;2(6):61-74.
17. Yoshioka S, Stella VJ. Stability of drugs and dosage forms. J Pharm Sci. 2000;89(1):1–10.
18. Sriramula JR, Shivaraj S. Analytical Method Development and Validation for the Estimation of Combined Antineoplastic Agents by RP-HPLC. IJPDA [Internet]. 2025Jul.7 [cited 2026Apr.26];13(3):1-5.
19. Mylsamy P, Bhingaradiya S, Elumalai S, Dantinapalli LS. Stability Indicating Method Development and Validation of Vadadustat by Using Hplc in Bulk and Pharmaceutical Dosage Form. World Journal of Current Medical and Pharmaceutical Research. 2026 Feb 22;27–32.
20. Li S, Bowden P. Chemical stability of pharmaceuticals. J Pharm Biomed Anal. 2013;87:147–158.
21. Murali Krishnam Raju P, Shyamala P, Venkata Narayana B, Kondra S, Mantena BPV. Assay of tirofiban and identification of oxidative impurity in aqueous injection by using UPLC-PDA/QDa detectors. Annales PharmaceutiquesFrançaises. 2022 Jan;80(1):35–47.
22. Carstensen JT, Rhodes CT. Drug stability principles and practices. Drug Dev Ind Pharm. 2000;26(11):1085–1090.
23. Ahuja S, Scypinski S. Handbook of modern pharmaceutical analysis. J Chromatogr A. 2001;913(1–2):1–15.
24. Rawat T, Pandey IP. Forced degradation studies for drug substances and drug products-scientific and regulatory considerations. Journal of pharmaceuticalSciences and research. 2015 May 1;7(5):238.
25. Venkataraman S, Manasa M. Forced degradation studies: Regulatory guidance, characterization of drugs, and their degradation products-a review. DrugInvention Today. 2018 Feb 1;10(2).137-46
26. Sharma MK, Murugesan M. Forced degradation study an essential approach to develop stability indicating method. J Chromatogr Sep Tech.2017;8(1):349.
27. P. Erukulla, P.V. Narasimha Raju, K.T. Kumar Reddy, V.R. Singamaneni, A. Pathak, S. Kumar Yadav, M. Sandeep Kumar,A.A. Mohathasim Billah. Emerging Analytical Techniques for Detection of Environmental Pollutants: A Review. Adv. J.Chem. A, 2026, 9(6), 962-996.
28. R. Hechhu, K. Krishnan, V. Singamaneni, P.V.N. Raju, P. Erukulla, K.V. Kandimalla, R.H. Babu, N. Vidiyala, GC-MS-Based Phytochemical Analysis, In-depth ADMET Screening and Molecular Docking Targeting EGFR for Anticancer Potential, Chem. Methodol., 2026, 10(5) 465-488
29. S.M. Bairagi, J.G. Wagh, A.R. Thanage, P. Venkata Narasimha Raju, P. Erukulla, K. Vamsi Kandimalla, A. Manukonda, R. Hari Babu. Green Extraction, Antioxidant, and Hepatoprotective Evaluation of Calotropis procera Leaf Extract. Asian Journal of Green Chemistry, 10 (3) 2026, 430-449.
30. Carstensen JT, Rhodes CT. Drug stability, revised, and expanded: principles and practices. CRC press; 2000 Jul 28.
31. Campbell JM, Colombo S, Doyle JL, Filoti DI, Huebner G, Laurent Magnenat, et al. An industry perspective on the use of forced degradation studies to assess comparability of biopharmaceuticals. Journal of Pharmaceutical Sciences. 2023 Dec 1;
32. Tuteja, Jasdev Singh; Singh, Anamika; Narsinghani, Tamanna. An Inclusive Exploration of Forced Degradation Analysis of Some Therapeutic Categories of Drugs in the Last Decade. Journal of the Scientific Society 50(3):p 312-344, Sep–Dec 2023. |
33. Mukuntha Kumar N, Rao SV. RP-HPLC method development and validation for the simultaneous determination of Telmisartan and Atorvastatin in bulk and pharmaceutical dosage form. International Journal of Scientific Research. 2014;3(11):357-9.
34. Sutar SV, YeligarVeerendra C, Patil SS. A Review: Stability Indicating Forced Degradation Studies. Research Journal of Pharmacy and Technology. 2019;12(2):885.
2. Singh S, Bakshi M. Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm Technol. 2000;24(2):1–14.
3. ICH. Q1A(R2): Stability Testing of New Drug Substances and Products. International Council for Harmonisation; 2003.
4. Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, et al. The role of degradant profiling in pharmaceutical development. Adv Drug Deliv Rev. 2007;59(1):29–37.
5. ICH Q1A (R2), International Council for Harmonisation, 2003.
6. ICH Q1B, ICH, 1996.
7. ICH Q2 (R1), ICH, 2005.
8. Kovarik J.M., Mueller E.A., van Bree J.B., Tetzloff W., Kutz K. (1994). Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. Journal of Pharmaceutical Sciences, 83(3), 444–446.
9. Alsante K.M., Hatajik T.D., Lohr L.L., Sharp T.R. (2003). Isolation and identification of process-related impurities and degradation products from pharmaceutical drug candidates. Part 1. American Pharmaceutical Review, 6(1), 70–78.
10. Smela J.W. (2001). Regulatory considerations for impurities in drug products. Pharmaceutical Technology, 25(6), 56–60.
11. Kavita Chandramore, Sandeep Sonawane. Overview on Development and Validation of Force Degradation Studies with Stability Indicating Methods. Biosciences Biotechnology Research Asia. 2022 Dec 20;19(4):881–94.
12. Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Juçara Ribeiro Franca, et al. Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective. Journal of Pharmaceutical Sciences. 2023 Sep 1;112(12).
13. Roberto de Alvarenga Junior B, Lajarim Carneiro R. Chemometrics Approaches in Forced Degradation Studies of Pharmaceutical Drugs. Molecules. 2019 Oct 22;24(20):3804.
14. Kronsbein K, Nold V, Böhrer A, Presser B, Gaissmaier T, Schindowski K, et al. Advancing forced degradation studies: Design of experiments for enhanced structure-function relationship analysis in biotherapeutics. European Journal of Pharmaceutics and Biopharmaceutics. 2025 Sep;214:114787.
15. Mullani AK and Nargatti PI: Forced degradation study - a new approach for stress testing of drug substances and drug products. Int J Pharm Sci & Res 2021; 12(5): 2683-91
16. Deokate U, Gorde A. Forced degradation and stability testing: Strategies and analytical perspectives. PharmaTutor. 2014 Jun 1;2(6):61-74.
17. Yoshioka S, Stella VJ. Stability of drugs and dosage forms. J Pharm Sci. 2000;89(1):1–10.
18. Sriramula JR, Shivaraj S. Analytical Method Development and Validation for the Estimation of Combined Antineoplastic Agents by RP-HPLC. IJPDA [Internet]. 2025Jul.7 [cited 2026Apr.26];13(3):1-5.
19. Mylsamy P, Bhingaradiya S, Elumalai S, Dantinapalli LS. Stability Indicating Method Development and Validation of Vadadustat by Using Hplc in Bulk and Pharmaceutical Dosage Form. World Journal of Current Medical and Pharmaceutical Research. 2026 Feb 22;27–32.
20. Li S, Bowden P. Chemical stability of pharmaceuticals. J Pharm Biomed Anal. 2013;87:147–158.
21. Murali Krishnam Raju P, Shyamala P, Venkata Narayana B, Kondra S, Mantena BPV. Assay of tirofiban and identification of oxidative impurity in aqueous injection by using UPLC-PDA/QDa detectors. Annales PharmaceutiquesFrançaises. 2022 Jan;80(1):35–47.
22. Carstensen JT, Rhodes CT. Drug stability principles and practices. Drug Dev Ind Pharm. 2000;26(11):1085–1090.
23. Ahuja S, Scypinski S. Handbook of modern pharmaceutical analysis. J Chromatogr A. 2001;913(1–2):1–15.
24. Rawat T, Pandey IP. Forced degradation studies for drug substances and drug products-scientific and regulatory considerations. Journal of pharmaceuticalSciences and research. 2015 May 1;7(5):238.
25. Venkataraman S, Manasa M. Forced degradation studies: Regulatory guidance, characterization of drugs, and their degradation products-a review. DrugInvention Today. 2018 Feb 1;10(2).137-46
26. Sharma MK, Murugesan M. Forced degradation study an essential approach to develop stability indicating method. J Chromatogr Sep Tech.2017;8(1):349.
27. P. Erukulla, P.V. Narasimha Raju, K.T. Kumar Reddy, V.R. Singamaneni, A. Pathak, S. Kumar Yadav, M. Sandeep Kumar,A.A. Mohathasim Billah. Emerging Analytical Techniques for Detection of Environmental Pollutants: A Review. Adv. J.Chem. A, 2026, 9(6), 962-996.
28. R. Hechhu, K. Krishnan, V. Singamaneni, P.V.N. Raju, P. Erukulla, K.V. Kandimalla, R.H. Babu, N. Vidiyala, GC-MS-Based Phytochemical Analysis, In-depth ADMET Screening and Molecular Docking Targeting EGFR for Anticancer Potential, Chem. Methodol., 2026, 10(5) 465-488
29. S.M. Bairagi, J.G. Wagh, A.R. Thanage, P. Venkata Narasimha Raju, P. Erukulla, K. Vamsi Kandimalla, A. Manukonda, R. Hari Babu. Green Extraction, Antioxidant, and Hepatoprotective Evaluation of Calotropis procera Leaf Extract. Asian Journal of Green Chemistry, 10 (3) 2026, 430-449.
30. Carstensen JT, Rhodes CT. Drug stability, revised, and expanded: principles and practices. CRC press; 2000 Jul 28.
31. Campbell JM, Colombo S, Doyle JL, Filoti DI, Huebner G, Laurent Magnenat, et al. An industry perspective on the use of forced degradation studies to assess comparability of biopharmaceuticals. Journal of Pharmaceutical Sciences. 2023 Dec 1;
32. Tuteja, Jasdev Singh; Singh, Anamika; Narsinghani, Tamanna. An Inclusive Exploration of Forced Degradation Analysis of Some Therapeutic Categories of Drugs in the Last Decade. Journal of the Scientific Society 50(3):p 312-344, Sep–Dec 2023. |
33. Mukuntha Kumar N, Rao SV. RP-HPLC method development and validation for the simultaneous determination of Telmisartan and Atorvastatin in bulk and pharmaceutical dosage form. International Journal of Scientific Research. 2014;3(11):357-9.
34. Sutar SV, YeligarVeerendra C, Patil SS. A Review: Stability Indicating Forced Degradation Studies. Research Journal of Pharmacy and Technology. 2019;12(2):885.
Published
28/02/2026
Statistics
97 Views | 41 Downloads
Citatons
How to Cite
Byram, K. K., S. Patel, C. Patel, and S. K. Muthyam. “Forced Degradation Studies in Analytical Method Development for Pharmaceuticals: A Comprehensive Review”. International Journal of Pharmacognosy and Chemistry, Vol. 7, no. 1, Feb. 2026, pp. 1-8, doi:10.46796/ijpc.v7i1.841.
Issue
Section
Review Article
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
.